Osteoarthritis is a painful degenerative joint disease which includes cartilage loss, subchondral bone remodelling, osteophyte formation and soft tissue damage.
The
present study concludes that expression levels of adiponectin were higher in
the OA patients as compared to the healthy controls and might be associated
with OA prevalence.
Osteoarthritis is a painful degenerative
joint disease which includes cartilage loss, subchondral bone remodelling,
osteophyte formation and soft tissue damage. It leads to ongoing disability in
older adults due to irreversible outcomes. About 6–17% and 2–10%of people
suffer from knee and hip OA respectively. It is most prevalent in women over 60
years of age. It is the leading cause of total joint arthroplasty (TJA) and
therefore creates a considerable economic burden. The aetiology of
osteoarthritis [OA] is not clearly understood, and most of the evidence
suggests that OA is a systemic disorder with a multifactorial origin. The risk
factors include age, gender, obesity, injury, the risk of genetic bias.
Moreover, increasing evidence suggests that obesity is an integral element in the pathogenesis of OA. Sowers et al. indicated that an increase in mechanical burden on joints might be a proposed mechanism for the involvement of obesity in OA. However, Gabay et al. reported that obesity induces high inflammatory and metabolic environments that may play a crucial role in the onset of OA. Several early studies have suggested an association between OA and some adipokines in serum or synovial fluid. One of the mediators of interest is adiponectin that might be related with OA.
Adiponectin, a 28–30 kDa collagen-like
protein, is one of the most abundantly secreted adipose tissue proteins and the
only adipokine which is negatively correlated with obesity. Adiponectin poses
various effects in many metabolic conditions such as atherosclerosis, insulin
resistance, atherosclerosis, and myocardial infarction as well as in
inflammatory and anti-inflammatory processes have been intensely studied for
many years. However, the effects of adiponectin in OA pathogenesis are still controversial.
On the other hand, evidence has shown that human and murine chondrocytes
express function adiponectin receptors (AdipoR1 and AdipoR2). It was also found
that adiponectin treatment can lead to a dose-dependent increase in
pro-inflammatory factors such as interleukin -6 (IL-6), inducible nitric oxide
synthase (iNOS), metalloproteases (MMPs) in
cultured chondrocytes. All of these determinants can lead to the degradation of
the matrix, articular cartilage and results in OA. The higher levels of
adiponectin were observed in both plasma and synovial fluid of OA patients
compared with the healthy controls. A recent study shows a positive association
between adiponectin concentration and the Kellgren-Lawrence (KL) grading
scores.
On the other hand, few studies failed to
determine a statistical association between adiponectin and OA. Moreover,
another study data indicates a negative correlation between with radiographic
severity of OA that might play a preventive role in OA. The present study
conducted a meta-analysis to determine a relationship between the expression
levels of adiponectin and prevalence of OA.
Rationale
behind research:
The effects of adiponectin in the
pathogenesis of OA are controversial as the previous studies provide no
sufficient evidence to suggest a correlation between the association of
adiponectin and OA. Therefore, the present study conducted a meta-analysis to
determine a relationship between the expression levels of adiponectin and
prevalence of OA.
Objective:
The goal of the meta analysis was to
perform a meta-analysis to determine the specific association between the
expression level of adiponectin and osteoarthritis (OA).
Study outcomes:
Time Points: NA
Outcomes:
Baseline: There were
no significant differences observed at baseline
Study outcomes:
The
present meta-analysis revealed that expression levels of adiponectin were
significantly higher in OA patients than in healthy patients. The findings
support the results of previous studies that indicated that adipose tissue
metabolism was a key factor for the development of OA and thereby, adiponectin
may be closely related to the pathogenesis of OA. Pooled analysis also
indicated that levels of adiponectin were significantly upregulated in the
middle and late stage of OA compared to healthy control. The adiponectin levels
might be down-regulated in response to the elevating level of lipid metabolism.
The
results also indicated that adiponectin association was stronger in patients
with knee OA but not with knee or hip OA. Furthermore, the ethnicity stratified
analysis showed that adiponectin expression levels were higher in both
Caucasian and Asian OA subjects than in the controls suggesting that ethnic
differences not affect the outcomes. Therefore, the expression of adiponectin
can be used as a pivotal biomarker in the diagnosis of OA progression.
The results may provide a potential and reliable tool for synergistically diagnosing OA which might offer a new therapeutic target for OA therapy. There is a need for further research with large sample size and unbiased methods.
Lipids in Health and Disease (2018) 17:189
Association of osteoarthritis and circulating adiponectin levels: a systematic review and meta-analysis
Tang et al.
Comments (0)